Dr. Vikram Arora, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,048
Licensed in Alabama since 1994, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
AL license 17906 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Grandview Medical Center Birmingham, AL
- Coosa Valley Medical Center Sylacauga, AL
Medical groups
- Affinity Cardiovascular Specialists LLC (44 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,048
- Services billed
- 3,121
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 540 | 367 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 342 | 329 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 228 | 111 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 215 | 206 |
| Injection, regadenoson, 0.1 mg | 208 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 151 | 67 |
| Ultrasound of heart with probe in esophagus, with report | 139 | 135 |
| 3d ultrasound imaging of heart for evaluation of heart structure performed during ultrasound imaging of congenital heart defects | 138 | 134 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 133 | 67 |
| Ultrasound of heart blood flow, valves and chambers | 132 | 130 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 70 payments worth $36,107 in total to this clinician.
| Compensation for services other than consulting (speaking, faculty) | $32,115 |
|---|---|
| Travel and Lodging | $2,858 |
| Food and Beverage | $1,121 |
| Entertainment | $13.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $3,450 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,375 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $2,990 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $2,850 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $2,530 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $1,840 |
| Lilly USA, LLC Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,560 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 22, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Nashville, TN · in-kind | $1,200 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $3,450 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $1,840 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $2,850 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 24, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Montgomery, AL · in-kind | $650 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 22, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Nashville, TN · in-kind | $1,200 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $2,990 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $2,530 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Meridian, MS · in-kind | $1,008 |
| Lilly USA, LLC Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Lilly USA, LLC Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Lilly USA, LLC Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Optos, Inc. Jun 12, 2025 | Entertainment NFC-700; PANORAMIC OPHTHALMOSCOPE; OCT OPHTHALMOSCOPE · OPHTHALMOLOGY · in-kind | $13.65 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Lilly USA, LLC Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Lilly USA, LLC Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Lilly USA, LLC Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,560 |
| Lilly USA, LLC Jan 22, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,375 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $46,115 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
Boston Scientific Corporation · Completed · NCT04790344 - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.